Osteolysis

Zetagen Announces Publication in Pain Management of Early Data Using ZetaMet™ as a Potential Treatment for Bone Metastases

Retrieved on: 
Tuesday, October 10, 2023

Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced publication of early, human clinical data in the peer-reviewed journal Pain Management on ZetaMet™ for the treatment bone metastases.

Key Points: 
  • Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced publication of early, human clinical data in the peer-reviewed journal Pain Management on ZetaMet™ for the treatment bone metastases.
  • To view the publication via open access, go to: https://www.futuremedicine.com/doi/10.2217/pmt-2023-0069
    ZetaMet™ is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone.
  • The small molecule has been approved by the U.S. Food and Drug Administration (FDA) since 1971.
  • Zetagen is focused on the more than 620,000 people in the United States, and more globally, living with metastatic cancers.

Orthofix Announces First Presentation of Seven-Year Outcome Data for the M6-C Artificial Cervical Disc With Other Clinical and Scientific Abstracts at the ISASS Annual Meeting

Retrieved on: 
Thursday, June 1, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230601005376/en/
    Illustration of the Orthofix M6-C artificial cervical disc.
  • (Graphic: Business Wire)
    “We are pleased to support a wide range of abstracts and clinical data during the annual ISASS meeting, including the first presentation of the seven-year data from the M6-C artificial cervical disc U.S. IDE study,” said Kevin Kenny, President of Global Spine.
  • “M6-C Artificial Cervical Disc: Seven-Year Outcomes for Single-Level Total Disc Replacement with a Novel Viscoelastic Artificial Cervical Disc” – abstract presentation by Dr. Todd Lanman.
  • This abstract is the first public presentation of specific seven-year clinical results associated with the use of the M6-C artificial cervical disc for the treatment of single-level symptomatic cervical radiculopathy.

Hip Innovation Technology Strengthens Senior Leadership Team

Retrieved on: 
Wednesday, February 16, 2022

Dr. MacDonald is an internationally recognized hip and knee replacement thought leader.

Key Points: 
  • Dr. MacDonald is an internationally recognized hip and knee replacement thought leader.
  • He has received over 25 research grants for hip and knee replacement projects totaling over 5 million dollars.
  • He has published over 200 research papers and book chapters and has lectured at over 250 national and international meetings.
  • "Each step builds on previous successes, culminating in a pivotal FDA IDE clinical study planned for initiation in 2022.

POPE MCGLAMRY, P.C. FILES LAWSUIT AGAINST EXACTECH FOR DEFECTIVE HIP IMPLANT

Retrieved on: 
Tuesday, February 15, 2022

ATLANTA, Feb. 15, 2022 /PRNewswire/ --On February 11, 2022, Pope McGlamry filed a federal lawsuit against orthopedic device manufacturer, Exactech, Inc.

Key Points: 
  • ATLANTA, Feb. 15, 2022 /PRNewswire/ --On February 11, 2022, Pope McGlamry filed a federal lawsuit against orthopedic device manufacturer, Exactech, Inc.
  • A hip liner is the component inserted into the artificial hip socket or cup that interfaces with the femoral head or ball.
  • On February 11, 2022, Pope McGlamry filed a federal lawsuit against orthopedic device manufacturer, Exactech, Inc.
  • The Exactech hip liner at issue is the Connexion GXL Liner, which is made of irradiated ultra-high molecular weight polyethylene (UHMWPE).

AxioMed LLC Files PMA Module II of III targeting 2022 FDA Approval of The First and Only Viscoelastic Lumbar Disc Replacement to Complete an IDE Clinical Study

Retrieved on: 
Wednesday, February 2, 2022

MALDEN, Mass., Feb. 2, 2022 /PRNewswire-PRWeb/ --AxioMed's lumbar viscoelastic total disc replacement PMA Module II was submitted to the FDA on January 28th, 2022 .

Key Points: 
  • MALDEN, Mass., Feb. 2, 2022 /PRNewswire-PRWeb/ --AxioMed's lumbar viscoelastic total disc replacement PMA Module II was submitted to the FDA on January 28th, 2022 .
  • We anticipate similar demand to follow with introduction of the AxioMed lumbar disc replacement and more positive insurance reimbursement.
  • The AxioMed viscoelastic disc replacement is widely anticipated in the USA and internationally as a major innovation and advance in disc replacement technology.
  • It is the only viscoelastic lumbar disc to complete a USA IDE clinical study with 10+ years of follow-up.

ZetaMet™ Receives Health Canada Authorization for Phase 2a Study in Treating Metastatic Bone Lesions

Retrieved on: 
Tuesday, January 18, 2022

Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, today announced it has received authorization from Health Canada to conduct a Phase 2a study, examining the safety and efficacy of ZetaMet for the treatment of metastatic bone lesions.

Key Points: 
  • Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, today announced it has received authorization from Health Canada to conduct a Phase 2a study, examining the safety and efficacy of ZetaMet for the treatment of metastatic bone lesions.
  • The start of this study marks a critical point in the development of ZetaMet, said Bryan Margulies, PhD, chief scientific officer of Zetagen Therapeutics.
  • So far, our combination technology has, in preclinical studies, demonstrated its ability to resolve existing metastatic bone lesions, inhibit pain and stimulate targeted bone regeneration.
  • Our multi-patented, ZetaMet technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone.

Zetagen Therapeutics Awarded $2 Million USD Grant from the National Cancer Institute (NCI) for Phase 2 Study of ZetaMet™ for Treatment of Metastatic Bone Cancers

Retrieved on: 
Monday, December 13, 2021

The grant will be used for the Phase 2 clinical and commercial development of its ZetaMet technology.

Key Points: 
  • The grant will be used for the Phase 2 clinical and commercial development of its ZetaMet technology.
  • ZetaMet is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone.
  • Preclinical trials have successfully demonstrated ZetaMets ability to resolve existing metastatic bone lesions, inhibit pain and stimulate targeted bone regeneration.
  • Bone metastases are common among cancer patients and occur when cells from the primary cancerous tumor relocate to the bone.

ZetaMet™ Receives Breakthrough Device Designation from U.S. Food and Drug Administration (FDA) for Treatment of Metastatic Bone Cancers

Retrieved on: 
Wednesday, December 1, 2021

Previously known as ZetaFuse, ZetaMet is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone.

Key Points: 
  • Previously known as ZetaFuse, ZetaMet is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone.
  • The combination technology has, thus far, in preclinical studies, demonstrated its ability to resolve existing metastatic bone lesions, inhibit pain and stimulate targeted bone regeneration.
  • Bone metastases are common among cancer patients and occur when cells from the primary cancerous tumor relocate to the bone.
  • Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions.